ABSTRACT. To determine whether expression of the hepatic angiotensinogen (Ao) gene is modulated by 1 ) ontogeny, 2) pregnancy, 3) glucocorticoids, or 4) triiodothyroxine (T3), time-dated pregnant Wistar-Kyoto rats were studied at different gestational ages (15, 17, and 20 d) without the influence of hormonal treatment or were given a daily intraperitoneal injection of dexamethasone (Dex) or T3 for 5 d (chronic Dex or T3) or a single injection of Dex (acute Dex). Maternal and fetal hepatic Ao mRNA levels were detected by dot and Northern blot analysis by using a full-length rat Ao cDNA. Fetal Ao mRNA levels were lower than in their maternal counterparts and lower than in adult rats of either sex. Maternal hepatic Ao mRNA levels were markedly diminished. mRNA levels were their lowest at 15 d of gestation and increased progressively as gestation advanced, reaching a peak at 20 d of gestation. Chronic Dex treatment resulted in a 190% increase in maternal and a 370% increase in the fetal hepatic Ao mRNA levels. Acute Dex treatment resulted in a 260% increase in maternal hepatic Ao mRNA levels with no change in the fetus. Hepatic Ao mRNA levels increased to the nonpregnant level with acute and chronic Dex treatment. Chronic T3 treatment resulted in a 20% increase in maternal hepatic Ao mRNA levels, without alteration of fetal Ao gene expression. We conclude that 1 ) the fetal and pregnant state results in a profound decrease in maternal and fetal hepatic Ao gene expression, 2) Ao gene expression is regulated by glucocorticoids in the term fetal and maternal liver, and 3) chronic T3 treatment results in a modest increase in maternal hepatic Ao gene expression. (Pediatr Res 30: 252-255,1991) Abbreviations Ao, angiotensinogen T3, L-triiodothyronine Dex, dexamethasone WKY, Wistar-Kyoto 32P, phosphorous 32
thyroxine (T3), time-dated pregnant Wistar-Kyoto rats were studied at different gestational ages (15, 17, and 20 d) without the influence of hormonal treatment or were given a daily intraperitoneal injection of dexamethasone (Dex) or T3 for 5 d (chronic Dex or T3) or a single injection of Dex (acute Dex). Maternal and fetal hepatic Ao mRNA levels were detected by dot and Northern blot analysis by using a full-length rat Ao cDNA. Fetal Ao mRNA levels were lower than in their maternal counterparts and lower than in adult rats of either sex. Maternal hepatic Ao mRNA levels were markedly diminished. mRNA levels were their lowest at 15 d of gestation and increased progressively as gestation advanced, reaching a peak at 20 d of gestation. Chronic Dex treatment resulted in a 190% increase in maternal and a 370% increase in the fetal hepatic Ao mRNA levels. Acute Dex treatment resulted in a 260% increase in maternal hepatic Ao mRNA levels with no change in the fetus. Hepatic Ao mRNA levels increased to the nonpregnant level with acute and chronic Dex treatment. Chronic T3 treatment resulted in a 20% increase in maternal hepatic Ao mRNA levels, without alteration of fetal Ao gene expression. We conclude that 1 ) the fetal and pregnant state results in a profound decrease in maternal and fetal hepatic Ao gene expression, 2) Ao gene expression is regulated by glucocorticoids in the term fetal and maternal liver, and 3) chronic T3 treatment results in a modest increase in maternal hepatic Ao gene expression. All components of the circulating renin-angiotensin system are present in the adult, newborn, and maturing fetus (1-3). The prohormone Ao serves as substrate for the renin-angiotensin cascade and, as such, is the only known precursor of the vasoactive hormone angiotensin 11. We have recently demonstrated that angiotensinogen gene expression is developmentally regulated in a tissue-specific manner with hepatic angiotensinogen mRNA levels markedly lower in the fetus than in the newborn or adult (4) . Whereas aspects of the regulation of angiotensinogen gene expression have been partially studied in the adult animal (5) (6) (7) (8) , the mechanisms regulating angiotensinogen gene expression in the fetal or pregnant rat have not been previously investigated.
The present study was designed to investigate the response of the fetal and pregnant rat hepatic angiotensinogen gene to the pregnant state, glucocorticoid, and T3 administration.
MATERIALS AND METHODS
Animal preparation. Twenty-nine time-dated pregnant WKY rats (Charles River Breeding Laboratories, Inc., Boston, MA) were housed at the University of Virginia Vivarium in opaque polypropylene cages with standard Rat Chow (Purina 5012; Ralston-Purina, St. Louis, MO) and tap water available ad libitum throughout the study. Animal quarters were air-conditioned and had a 12-h light/dark cycle with lights on at 0800 h.
Effect of pregnancy on maternal hepatic Ao gene expression.
Nine time-dated pregnant WKY rats were divided into groups ofthree and were killed on d 15, 17, and 20 of gestation. Maternal livers were immediately removed, frozen in liquid nitrogen, and stored at -70°C until processed for Ao mRNA determinations.
Effect of acute and chronic Dex and T3 on fetal and maternal hepatic Ao gene expression. Chronic studies were performed starting at d 15 of gestation. The pregnant rats were divided into groups receiving either no treatment (control, n = 3) or a daily intraperitoneal injection with saline vehicle (vehicle, n = 3), Dex phosphate (Elkins-Sinn, Cherry Hill, NJ) 10 mg/kg ( n = 3), or 10 ~g / k g of T3 (Sigma Chemical Co., St. Louis, MO) ( n = 2) each morning for 5 consecutive days. On the morning of 20 d of gestation, the animals were given intraperitoneal injections of sodium pentobarbital and were killed by decapitation. Maternal and fetal livers were rapidly removed, frozen in liquid nitrogen, stored at -70"C, and processed as described above. A total of 99 fetuses and 11 adult rats were examined. Fetal tissues from each litter were pooled to determine the biologic mean for fetal Ao mRNA.
For acute experiments, time-dated WKY rats on d 20 of gestation were given either a single intraperitoneal injection of vehicle (saline) ( n = 5) of 10 mg/kg of Dex ( n = 5) and killed as described above after 6 h. Maternal and fetal livers were removed and processed as described above. A total of 74 fetuses and 10 adult rats were examined. Fetal tissues from each litter were pooled as described above.
Extraction, electrophoresis, and hybridization of RNA to complementary DNA. RNA was extracted by the method of Chirgwin et al. (9) . RNA concentrations were determined spectrometrically at 260 nm. Electrophoresis and hybridization of RNA was performed as previously described (4). Briefly, RNA was denatured by heating for 10 min at 65°C in 4.4 M formaldehyde-50% formamide and resolved by electrophoresis on a 1.0% agarose gel containing 2.2 M formaldehyde. The RNA was transferred to a positively charged nylon 66 membrane (Zetabind; AMF Cuno, Meriden, CT) by capillary action (Northern blot). The bound RNA was heated in vacuo at 80°C for 1 h, exposed to UV light from an UV transilluminator (254 nm, 500 pW/cm2) for 1 min, dried, and stored until hybridized as described below. Dot blots were prepared by dissolving 1.00-0.125 pg total RNA in 0.5 mL of sterile 25 mM sodium phosphate buffer (pH 7.2) and applying this RNA to a Zetabind membrane preequilibrated with the same buffer.
Dot and Northern blots were hybridized by the method of Church and Gilbert (10) with a full-length (1.6-kb) rat Ao cDNA (gift of Dr. K. Lynch, University of Virginia) labeled with 32P by nick translation (1 1) as we previously described (4). Signals were detected by autoradiography by using an intensifying screen with multiple exposures made within the linearity of Kodak AR and RP film. Messenger RNA determinations were performed by laser densitometry (LKB Laser Densitometer, Bromma, Sweden) with each well scanned three times, and the average absorbance was expressed as a percentage of increase or decrease between groups. All densitometric comparisons between groups were from the same autoradiograph. Northern blots were performed in parallel with dot blots to confirm the lack ofRNA degradation.
As a control for RNA degradation and to confirm whether observed differences in Ao mRNA acumulation were gene specific, Northern blots were performed in duplicate and were also hybridized to a P-actin cDNA prepared from a rat aorta DNA library (a gift of Dr. Gary Owens and Marcie Co jay, University of Virginia).
RESULTS
All maternal and fetal hepatic RNA samples were intact and possessed the correct electrophoretic mobility without degradation as demonstrated by comparable hybridization to P-actin cDNA in the experimental and control groups. In addition, Pactin gene expression was unaltered by Dex treatment or pregnancy in the maternal or fetal groups (data not shown).
Effect of pregnancy on maternal hepatic Ao gene expression. The expression of maternal hepatic Ao mRNA changed markedly throughout the last third of gestation (Fig. 1) . Hepatic Ao mRNA levels in untreated pregnant rats were markedly decreased at 15 d gestation (15 D), with levels gradually increasing at 17 d gestation (1 7 D) to maximal levels at 20 d gestation (20 D) . In addition, maternal hepatic Ao mRNA levels were markedly lower than Ao mRNA levels in the adult nonpregnant female (AF, Fig. 1 ) or in the adult male (AM, see Fig. 2 ). Thus, pregnancy appears to result in a profound downregulation in Ao gene expression during the last third of gestation.
Effect of ontogeny. As demonstrated by Figures 2B and 3B, during fetal life hepatic Ao mRNA is barely detectable by Northern analysis and, regardless of the treatment status, fetal Ao mRNA levels were always lower than maternal levels or those observed in adult rats of either sex ( Figs. 2A and B and 3A and  B) . Therefore, during fetal life, there is a profound reduction in hepatic Ao gene expression.
Effect of chronic Dex and T3 on maternal and fetal Ao gene expression. The response of maternal and fetal Ao mRNA levels to Dex and T3 are shown in Figure 2 . The dot blot analysis of Figure 2A demonstrates that chronic Dex administration resulted in increased hepatic Ao mRNA levels in both the maternal and fetal livers (D). Densitometric analysis demonstrated a 190% increase in maternal and a 370% increase in fetal hepatic Ao levels. T3 (T) treatment increased maternal hepatic Ao gene expression 20%, although fetal gene expression was not altered. Regardless of the treatment status, fetal Ao mRNA levels were always lower than maternal levels. As shown in Figure 2B , fetal liver Ao mRNA at term is barely detectable by Northern analysis even with chronic Dex stimulation.
Effect of acute Dex on maternal and fetal Ao gene expression. To determine if the maternal and fetal hepatic Ao gene response to Dex was a time-related phenomenon, the maternal and fetal hepatic response to acute Dex administration at 20 d of gestation is shown in the dot blot of Figure 3A . Acute Dex administration increased maternal hepatic Ao mRNA by 260% when compared film with an intensifying screen. Abbreviations are as described for A. (15, 18, 19) . Therefore, the difference in maternal and fetal hepatic responses at term to acute Dex stimulation could possibly be because of altered responsiveness and heterogeneity of fetal glu- Fig, 3 
tion.
Thyroid hormones are known to increase production and with vehicle-treated rats. However, acute Dex administration secretion of A0 from liver slices and, in the Reuber H35 induced no changes in fetal AO mRNA concentration (D versus rat hepatoma cell line, the increase in A0 production and secrev). tion is associated with an increase in Ao mRNA (14) . In the present study, unlike Dex, chronic administration (5 d) of T3 DISCUSSION modestly increased maternal hepatic Ao mRNA accumulation without altering fetal hepatic Ao gene expression. As previously The present study demonstrates the following points. 1 ) demonstrated, the placenta is relatively impermeable to T3 and Expression of the hepatic Ao gene is lower in the fetal rat than thyroxine (22, 23) . Thus, the lack of fetal response is most likely in the adult male, virgin female, or pregnant rat. 2 ) Despite low related to the inability to significantly increase circulating T3 in basal levels of expression, the Ao gene is regulated by Dex in the the fetus. In the intact adult animal, the hepatic A0 gene is poorly term fetus. 3) During pregnancy, maternal hepatic Ao gene responsive to T3 alone. Sernia a/. (24) by using adult male expression is reduced. However, the maternal liver is more rats, also demonstrated only a 20% increase in hepatic mRNA responsive than the fetal liver to acute Dex stimulation. 4) The after 10 d of T3 treatment. Although T3 alone induces a small maternal Ao gene is modestly responsive to T3. increase in Ao mRNA levels, as others have suggested, T3 may As we previously reported, hepatic A0 mRNA levels are lower act primarily in a permissive fashion to enhance the action of during fetal life than at any other time point during ontogeny, other hormones such as glucocorticoids (14) . Further studies are increasing to adult levels dramatically within 24 h of birth (4) . necessary to determine the effect of T3 on fetal A0 gene expresThe present study confirms and extends those observations, sion. demonstrating that fetal Ao gene expression at term is also A0 gene regulation during Pregnancy has not been previously markedly less than in the pregnant, nonpregnant female, and described. In the present study, we determined that hepatic Ao male adult animals. The reasons for the differences between fetal mRNA concentrations are reduced in the pregnant rat, when and adult Ao mRNA levels are not clear. Because fetal Ao mRNA compared with the adult nonpregnant female or male rat, and increased rapidly hours after birth, we postulated that some of are gestationally regulated. Although Ao mRNA concentrations the complex neurohumoral changes surrounding partuition andl were decreased, the AO gene was still responsive to Dex. Previous or extrauterine life may have influenced the expression of fetal investigators have demonstrated that circulating levels of Ao and hepatic Ao gene (4). Among possible hormonal influences, we renin are increased during pregnancy (25, 26) . The elevation of postulated that steroid and thyroid hormones known to increase estrogens during pregnancy has been proposed as an explanation around the time of birth may stimulate fetal Ao gene expression for the increase in circulating Ao levels (26, 27) , implying an (4).
estrogen-mediated increase in Ao gene expression and synthesis. Steroid hormones exert their effects by intracellular glucocor-Although we did not obtain serum Ao levels as a comparison, ticoid receptor coupling; the receptor-ligand complex then inter-we report that Ao gene expression is reduced with pregnancy at acts with specific target DNA and modulates transcription of every day of gestation studied. The discrepancy between deselected genes (12) . The Ao gene, as described by Ohkubo et al. creased gene expression and circulating Ao levels could be ex- (8) , possesses homology with glucorticoid receptor-binding se-plained by the identification of multiple circulating forms of Ao quences in the 5'-flanking region and thus provides a basis for during pregnancy (27) ; at least one of the these Ao isoforms may have altered kinetics for renin (27) . Altered clearance of these multiple isoforms could possibly explain the descrepancy between high circulating Ao levels and low Ao mRNA expression. In addition, it is possible that alternate sources of Ao (such as placenta) may contribute to high levels of Ao seen during pregnancy. Further studies are needed to delineate the mechanisms regulating Ao gene expression during pregnancy and their potential impact on maternal hemodynamic regulation.
In conclusion, the rat maternal and fetal hepatic Ao gene can be regulated by glucocorticoids at term, possibly via active glucocorticoid receptors. This ability to enhance Ao gene expression with glucocorticoids in the fetal rat suggests an important role for Ao even during fetal life, possibly by mediating hemodynamic homeostasis and preparing the fetus for the transition to extrauterine life. The present study represents the first report of gestational regulation of maternal hepatic Ao gene expression. The mechanisms involved in the disproportionate downregulation of Ao gene expression and the reported increased circulating Ao activity during pregnancy are unknown and are under further investigation. Further studies are needed to determine the homeostatic regulation of Ao and renin during pregnancy and their impact on cardiovascular control.
